KInhibition: Kinase Inhibitor Selection Portal

Kinase(s) of Interest



1. Select the kinase(s) to inhibit. Note that selecting more than one compound may result in poor selectivity for most compounds.

2. Select a dataset to search (see "Datasets" tab on the right). Note that only datasets containing all kinases selected will be available.

3. View the Table of Results tab to view the properties of the compounds. See below the table for descriptions of the column headers.

4. Customize the results shown in the table by using the column headers to sort the compounds by various properties, the dropdown menu in the upper left to show more or fewer compounds, or the search bar in the upper right to find a specifc entry.

5. Check off-target effects of the compounds in the table by clicking on the desired compound. Non-chosen kinases with inhibition higher than half of the inhibition of the chosen kinase(s) will be shown below.

6. View the Heatmap tab to visualize the inhibition profiles of the compounds present in the "Table of Results". Mouse over cells in the heatmap for more information.

7. Download the tables or heatmaps using the buttons below them.

Please cite the following publication for use of this tool:

Bello, T., & Gujral, T. S. (2018). KInhibition: A Kinase Inhibitor Selection Portal. iScience.

Disclaimer: This application should not be considered, or used as a substitute for, medical advice, diagnosis or treatment. This site does not constitute the practice of any medical, nursing or other professional health care advice, diagnosis or treatment.

Please note that heatmap may take a few seconds to fully load, update, or download.
To change or update the data being displayed, use the Table of Results tab.

Reaction Biology (KiR 1)

This screen was performed through a collaboration between the Fox Chase Cancer Center and Reaction Biology Corporation. Details about the assay can be found in the original publication.

The data can also be explored here.

Citation: Anastassiadis, T., Deacon, S. W., Devarajan, K., Ma, H., & Peterson, J. R. (2011). Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity. Nature Biotechnology, 29(11), 1039-1045.

Number of Compounds: 178
Number of compound/dose combinations: 178
Number of kinases: 300
Pairwise Coverage: 98.9%


The Library of Integrated Network-based Cellular Signatures (LINCS) is an NIH-funded program at Harvard Medical School. This dataset uses the KINOMEscan Assay to profile kinases bound by inhibitors.

The resulting datasets can be accessed here.

Citation: Koleti, A., Terryn, R., Stathias, V., Chung, C., Cooper, D. J., Turner, J. P., . Schurer, S. C. (2017). Data Portal for the Library of Integrated Network-based Cellular Signatures (LINCS) program: integrated access to diverse large-scale cellular perturbation response data. Nucleic Acids Research.

Number of Compounds: 121
Number of compound/dose combinations: 134
Number of kinases: 471
Pairwise Coverage: 88.5%


A library of the GlaxoSmithKline (GSK) Published Kinase Inhibitor Set (PKIS) was assayed at the NIH using luciferase reporter enzymes. Details about the assay can be found in below publication.

The published datasets can be accessed by following the instructions found here.

Citation: Dranchak, P., MacArthur, R., Guha, R., Zuercher, W. J., Drewry, D. H., Auld, D. S., & Inglese, J. (2013). Profile of the GSK Published Protein Kinase Inhibitor Set Across ATP-Dependent and-Independent Luciferases: Implications for Reporter-Gene Assays. PLoS ONE, 8(3), e57888.

Number of Compounds: 367
Number of compound/dose combinations: 734
Number of kinases: 224
Pairwise Coverage: 99.9%

EMD Millipore

Pairwise assays between purified recombinant human kinases and a collection of small molecule inhibitors were carried out by the EMD Millipore Corporation (now known as Millipore Sigma) using a filter binding radioactive ATP transferase assay.

Raw data and details on the recombinant kinases and inhibitors used can be found in the supplemental files of the original publication here.

Citation: Gao, Y., Davies, S. P., Augustin, M., Woodward, A., Patel, U. A., Kovelman, R., & Harvey, K. J. (2013). A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. Biochemical Journal, 451(2), 313-328.

Number of Compounds: 128
Number of compound/dose combinations: 255
Number of kinases: 234
Pairwise Coverage: 100%

Submitting a New Dataset

If there is a dataset or compound screen that you would like to see included in this tool, please contact the authors of the publication (link in sidebar).

File Guidelines for Submitting a Dataset:

  1. File should be in (.csv) format. Excel 2007+ (.xlsx) format is also acceptable, but DO NOT use (.xls) as this may lead to truncation and loss of data.
  2. Only characters on a standard US keyboard should be used throughout the file (e.g. use "u" in place of a greek mu).
  3. First column should be labeled "Compound" and contain compound names, with aliases in parentheses.
    Ex: Dorsomorphin (BML-275, Compound C)
  4. Second column should be a unique identifier, preferably CAS numbers. Columnn header should be "CAS" or appropriate identifier name.
  5. Third column should be labeled "Dose" and contain the dose and unit (no spaces) of the compound tested.
  6. All subsequent column headers should be standardized kinase names (see below for kinase naming conventions).
  7. All entries in the table must be numerical, percent-of-control inhibition values between 0 and 100 (100 = total inhibition, 0 = no inhibition compared to control), or "NA" for missing values.
  8. Include the source citation / publication for the data or otherwise demonstrate data access permission.

Kinase Naming Conventions:

  1. Use the HGNC gene names (in all caps) for all protein names.
  2. Do not include any whitespace characters (spaces, tabs, newlines, etc) in kinase names.
  3. Indicate mutations in parentheses as "(X###Y)". Separate additional mutations with a comma, and indicate deleted regions with "del".
    Ex: EGFR(L747-E749del,A750P).
  4. Include complexed or bound proteins with their HGNC gene names, separated by a "+".
    Ex: CDK2+CCNA2
  5. Denote activated (cleaved, etc.) forms without distinct HGNC names with "(a)".
    Ex: CDK5+CDK5R1(a)
  6. Denote inactivated or inhibited forms with "(i)".
  7. Denote phosphorylated proteins with "(p)".
  8. Denote non-mutant variants (e.g. splice variants) without distinct HGNC names with "(v2)", "(v3)", etc., but do not use "(v1)" for the most common variant.
    Ex: LYN, LYN(v2)
  9. Denote multiple domains of the same kinase screened separately with "(dom1)", "(dom2)", etc., numbered from N-terminus to the C-terminus.
    Ex: JAK1(dom1), JAK1(dom2)